MX354215B - Inhibidores de la proteina 90 de choque termico (hsp90). - Google Patents
Inhibidores de la proteina 90 de choque termico (hsp90).Info
- Publication number
- MX354215B MX354215B MX2013011531A MX2013011531A MX354215B MX 354215 B MX354215 B MX 354215B MX 2013011531 A MX2013011531 A MX 2013011531A MX 2013011531 A MX2013011531 A MX 2013011531A MX 354215 B MX354215 B MX 354215B
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- pharmaceutically acceptable
- independently
- compound
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La descripción se refiere a compuestos de la fórmula (1) y sales farmacéuticamente aceptables de los mismos, en donde (a) cada uno de Z1, Z2 y Z3 es independientemente CH o N; (b) Y es S; (c) Xa y Xb son O; Cd) Xc es -CH; (e) X2 es -NR1R2, en donde R1 y R2 son cada uno independientemente H, C1-C6 alquilo, C2-C6 alquenilo, C2-C6 alquinilo, cicloalquilo, heteroalquilo, heterocicloalquilo, arilo, heteroarilo, alquilarilo, arilalquilo, heteroarilo, heteroarilalquilo, o alquilheteroarilalquilo; (f) X4 es hidrógeno o halógeno; y (g) R es R10-NH-R11 en donde R10 es etileno o propileno, y R11 es un alquilo ramificado. Composiciones que comprenden una cantidad efectiva de un compuesto de la Fórmula (1) o una sal farmacéuticamente aceptable del mismo y métodos para tratar y prevenir una condición, tal como cáncer que sobreexpresa Her-cinasas, que comprende administrar a un paciente en necesidad de lo mismo una cantidad terapéuticamente efectiva de un compuesto de la Fórmula (1) o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161472061P | 2011-04-05 | 2011-04-05 | |
| PCT/US2012/032373 WO2012138896A1 (en) | 2011-04-05 | 2012-04-05 | Hsp90 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013011531A MX2013011531A (es) | 2014-08-22 |
| MX354215B true MX354215B (es) | 2018-02-19 |
Family
ID=46018086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013011531A MX354215B (es) | 2011-04-05 | 2012-04-05 | Inhibidores de la proteina 90 de choque termico (hsp90). |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9546170B2 (es) |
| EP (1) | EP2694506B1 (es) |
| JP (1) | JP5961683B2 (es) |
| KR (1) | KR101984480B1 (es) |
| CN (1) | CN103596955B (es) |
| AU (1) | AU2012240079B2 (es) |
| BR (1) | BR112013025761A2 (es) |
| CA (1) | CA2832099C (es) |
| EA (1) | EA024647B1 (es) |
| ES (1) | ES2647889T3 (es) |
| MX (1) | MX354215B (es) |
| WO (1) | WO2012138896A1 (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| JP5599610B2 (ja) | 2006-06-30 | 2014-10-01 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| CN105924443A (zh) | 2009-10-07 | 2016-09-07 | 斯隆-凯特林癌症研究院 | 用作Hsp90抑制剂的嘌呤衍生物 |
| CN103596955B (zh) | 2011-04-05 | 2016-11-16 | 索隆-基特林癌症研究协会 | Hsp90抑制剂 |
| KR102010222B1 (ko) | 2011-04-05 | 2019-08-13 | 슬로안-케테링인스티튜트퍼캔서리서치 | Ｈｓｐ９０ 억제제 |
| US20140294725A1 (en) | 2011-07-08 | 2014-10-02 | Sloan-Kettering Institute For Cancer Research | Uses of labeled hsp90 inhibitors |
| HRP20240514T1 (hr) | 2012-02-09 | 2024-07-05 | The University Of Kansas | Međuproizvodi za pripremu c-terminalnih inhibitora hsp90 |
| TW201533043A (zh) * | 2013-04-18 | 2015-09-01 | Lundbeck & Co As H | 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物 |
| CN105899503B (zh) | 2013-08-16 | 2020-08-18 | 纪念斯隆-凯特琳癌症中心 | 选择性grp94抑制剂和其用途 |
| KR102325454B1 (ko) | 2013-12-23 | 2021-11-16 | 메모리얼 슬로안 케터링 캔서 센터 | 방사성표지화를 위한 방법 및 시약 |
| CA2952029A1 (en) | 2014-06-24 | 2015-12-30 | The University Of Kansas | Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers |
| US10617772B2 (en) | 2014-09-17 | 2020-04-14 | Memorial Sloan Kettering Cancer Center | Hsp9O-targeted inflammation and infection imaging and therapy |
| AU2016336351A1 (en) | 2015-10-05 | 2018-05-10 | Memorial Sloan Kettering Cancer Center | Rational combination therapy for the treatment of cancer |
| WO2019222269A1 (en) | 2018-05-14 | 2019-11-21 | Reata Pharmaceuticals, Inc. | Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway |
| WO2023006993A1 (en) | 2021-07-30 | 2023-02-02 | Atmosr | Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome |
| WO2024194175A1 (en) * | 2023-03-17 | 2024-09-26 | Atmosr | Adenine derivatives as hsp90 inhibitors |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69841549D1 (de) | 1997-05-14 | 2010-04-22 | Sloan Kettering Inst Cancer | Verfahren und zubereitungen zur zerstörung bestimmter proteine |
| WO2000061578A1 (en) | 1999-04-09 | 2000-10-19 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
| WO2002036075A2 (en) | 2000-11-02 | 2002-05-10 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to hsp90 |
| CA2450167A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
| EP1440072A4 (en) | 2001-10-30 | 2005-02-02 | Conforma Therapeutic Corp | PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY |
| AU2002356922A1 (en) | 2001-11-09 | 2003-05-26 | Conforma Therapeutics Corporation | Hsp90-inhibiting zearalanol compounds and methods of producing and using same |
| MXPA04008312A (es) | 2002-02-28 | 2004-11-26 | Astrazeneca Ab | Derivados de 3-cilil-5-(anillo de 5 miembros que contienen nitrogeno)-metil-oxazolidinona y sus uso como agentes antibacterianos. |
| WO2004094647A2 (en) | 2003-04-18 | 2004-11-04 | Cytovia, Inc. | Methods of treating diseases responsive to induction of apoptosis and screening assays |
| US7148228B2 (en) | 2003-09-18 | 2006-12-12 | Conforma Therapeutics Corporation | Pyrazolopyrimidines and related analogs as HSP90-inhibitors |
| US7834181B2 (en) | 2005-02-01 | 2010-11-16 | Slaon-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| US9403828B2 (en) | 2005-02-01 | 2016-08-02 | Sloan-Kettering Institute For Cancer Research | Small-molecule Hsp90 inhibitors |
| CN101296909B (zh) | 2005-08-26 | 2011-10-12 | 默克雪兰诺有限公司 | 吡嗪衍生物及其作为pi3k抑制剂的应用 |
| JP2009521446A (ja) | 2005-12-22 | 2009-06-04 | コンフォーマ・セラピューティクス・コーポレイション | 熱ショックタンパク質９０の経口活性なプリンベースの阻害剤 |
| WO2007134298A2 (en) | 2006-05-12 | 2007-11-22 | Myriad Genetics, Inc. | Therapeutic compounds and their use in cancer |
| JP5599610B2 (ja) | 2006-06-30 | 2014-10-01 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| AU2007296744A1 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Multi-functional small molecules as anti-proliferative agents |
| FR2906824B1 (fr) | 2006-10-09 | 2008-12-26 | Roger Mondelin Sas Soc Par Act | Dispositif support de butees pour la pose de plaques de platre de largeur variable avec des appareils de levage et de manutention desdites plaques |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| GB0622084D0 (en) | 2006-11-06 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of HSP90 |
| US20080234297A1 (en) | 2007-03-20 | 2008-09-25 | Changgeng Qian | HSP90 Inhibitors Containing a Zinc Binding Moiety |
| EP2069324B1 (en) | 2007-03-20 | 2013-07-31 | Curis, Inc. | Fused amino pyridine as hsp90 inhibitors |
| EP2183221A1 (en) | 2007-07-12 | 2010-05-12 | Crystax Pharmaceuticals S.L. | New compounds as hsp90 inhibitors |
| WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| NZ586129A (en) | 2007-11-14 | 2012-06-29 | Myrexis Inc | Therapeutic compounds and their use in treating diseases and disorders |
| CA3017874A1 (en) | 2009-01-16 | 2010-07-22 | Curis, Inc. | Fused amino pyridines for the treatment of brain tumors |
| CN105924443A (zh) | 2009-10-07 | 2016-09-07 | 斯隆-凯特林癌症研究院 | 用作Hsp90抑制剂的嘌呤衍生物 |
| KR102010222B1 (ko) | 2011-04-05 | 2019-08-13 | 슬로안-케테링인스티튜트퍼캔서리서치 | Ｈｓｐ９０ 억제제 |
| CN103596955B (zh) | 2011-04-05 | 2016-11-16 | 索隆-基特林癌症研究协会 | Hsp90抑制剂 |
| CN105899503B (zh) | 2013-08-16 | 2020-08-18 | 纪念斯隆-凯特琳癌症中心 | 选择性grp94抑制剂和其用途 |
-
2012
- 2012-04-05 CN CN201280027360.XA patent/CN103596955B/zh not_active Expired - Fee Related
- 2012-04-05 MX MX2013011531A patent/MX354215B/es active IP Right Grant
- 2012-04-05 ES ES12717521.4T patent/ES2647889T3/es active Active
- 2012-04-05 CA CA2832099A patent/CA2832099C/en active Active
- 2012-04-05 AU AU2012240079A patent/AU2012240079B2/en not_active Ceased
- 2012-04-05 EP EP12717521.4A patent/EP2694506B1/en active Active
- 2012-04-05 JP JP2014503996A patent/JP5961683B2/ja not_active Expired - Fee Related
- 2012-04-05 US US14/110,095 patent/US9546170B2/en active Active
- 2012-04-05 KR KR1020137029258A patent/KR101984480B1/ko active IP Right Grant
- 2012-04-05 WO PCT/US2012/032373 patent/WO2012138896A1/en active Application Filing
- 2012-04-05 BR BR112013025761A patent/BR112013025761A2/pt not_active IP Right Cessation
- 2012-04-05 EA EA201391337A patent/EA024647B1/ru not_active IP Right Cessation
-
2016
- 2016-12-09 US US15/374,007 patent/US10064867B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2013011531A (es) | 2014-08-22 |
| US9546170B2 (en) | 2017-01-17 |
| WO2012138896A1 (en) | 2012-10-11 |
| CA2832099A1 (en) | 2012-10-11 |
| US20170151247A1 (en) | 2017-06-01 |
| KR20140073464A (ko) | 2014-06-16 |
| KR101984480B1 (ko) | 2019-05-31 |
| AU2012240079A1 (en) | 2013-11-07 |
| JP2014510149A (ja) | 2014-04-24 |
| AU2012240079B2 (en) | 2017-05-18 |
| EA201391337A1 (ru) | 2014-05-30 |
| CN103596955B (zh) | 2016-11-16 |
| BR112013025761A2 (pt) | 2018-05-29 |
| ES2647889T3 (es) | 2017-12-27 |
| CN103596955A (zh) | 2014-02-19 |
| EP2694506A1 (en) | 2014-02-12 |
| EA024647B1 (ru) | 2016-10-31 |
| CA2832099C (en) | 2019-07-09 |
| EP2694506B1 (en) | 2017-09-20 |
| JP5961683B2 (ja) | 2016-08-02 |
| US10064867B2 (en) | 2018-09-04 |
| NZ616890A (en) | 2016-01-29 |
| US20140045867A1 (en) | 2014-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX354215B (es) | Inhibidores de la proteina 90 de choque termico (hsp90). | |
| MX2013011532A (es) | Inhibidores de la proteina 90 de choque termico (hsp90). | |
| NZ603155A (en) | Phospholipid drug analogs | |
| JP2014510149A5 (es) | ||
| MX352672B (es) | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. | |
| CR20140301A (es) | Derivados de betulina | |
| TN2015000121A1 (en) | Gdf-8 inhibitors | |
| PH12015502675A1 (en) | Cycloaklane derivative | |
| MX2014001595A (es) | Compuestos de imidazol, composiciones y metodos de uso. | |
| TN2015000102A1 (en) | Bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors | |
| DOP2014000058A (es) | 3- pirmidin- 4- il- oxazolidin- 2- onas como inhibidores de la idh mutante | |
| MX2010007375A (es) | Nuevos derivados de lupano. | |
| MX2015012427A (es) | Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer. | |
| MY172924A (en) | Neprilysin inhibitors | |
| MX2021001486A (es) | Inhibidores prmt5. | |
| MX353500B (es) | Compuesto heterociclico. | |
| MX2013003019A (es) | Compuestos de azabenzotiazol, composiciones y metodos de uso. | |
| MX2013011589A (es) | Metodos y composiciones para tratar enfermedad de parkinson. | |
| EA201170617A1 (ru) | Пиразолиламинопиридины в качестве ингибиторов fak | |
| WO2014078295A8 (en) | Gemcitabine prodrugs and uses thereof | |
| MX344933B (es) | Compuestos de lipoílo y su uso para tratar lesión isquémica. | |
| IN2014CN04449A (es) | ||
| PH12016500838A1 (en) | Isoxazolines as therapeutic agents | |
| NZ712660A (en) | Dicarboxylic acid compound | |
| MX2013007938A (es) | Compuesto biciclico novedoso o sal del mismo. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |